• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Xintela

0.19 SEK

-3.75 %

Less than 1K followers

XINT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-3.75 %
-22.06 %
-17.03 %
-32.22 %
-24.21 %
-55.40 %
-26.13 %
-88.68 %
-91.60 %

Xintela operates in biotechnology. The company's expertise is found in regenerative medicine, as well as the treatment of cancer, articular cartilage damage and brain tumors. The research is based on the development of protein molecules that have the capacity to sense changes on the surface of cells, which enables the identification of stem cells that are about to develop into cartilage cells. The company was founded in 2009 and is headquartered in Lund.

Read more
Market cap
165.79M SEK
Turnover
1.46K SEK
Revenue
2.28M
EBIT %
-2,045.75 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.8
2026

Interim report Q2'26

27.11
2026

Interim report Q3'26

26.2
2027

Annual report '26

Third party research6/4/2026, 6:58 AM

Xintela: Completing another phase I/IIa study - VH Corp

• Considering the alternatives in wound treatment • Discussions about investigator-initiated studies continue • We keep our fair value at SEK 1.04 per share On the day of the Q1 report, Xintela announced positive results of its phase I/IIa study of XSTEM...

Xintela
Press release6/4/2026, 6:00 AM

Västra Hamnen Market Focus: Xintela: Completing another phase I/IIa study

Xintela
Regulatory press release5/29/2026, 12:25 PM

Xintela AB Interim Report January - March 2026

Xintela

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/29/2026, 8:00 AM

Xintela reports safety results from the XSTEM clinical study in difficult-to-heal venous leg ulcers

Xintela
Regulatory press release5/28/2026, 11:00 AM

Xintela AB changes Certified Adviser to Västra Hamnen Corporate Finance AB

Xintela
Press release5/12/2026, 11:15 AM

Xintela granted patent in Japan for XSTEM® treatment of acute respiratory distress syndrome (ARDS)

Xintela
Regulatory press release4/30/2026, 5:50 AM

Xintela AB publishes Annual Report 2025

Xintela
Press release4/14/2026, 11:05 AM

Xintela granted US patent for XSTEM treatment of difficult-to-heal wounds and skin defects

Xintela
Press release4/13/2026, 9:15 PM

Xintela publication on EQSTEM treatment of horses in a preclinical osteoarthritis study awarded best basic science paper

Xintela
Third party research3/3/2026, 8:21 AM

Xintela: Moving forward with XSTEM - VH Corp

* Professor Hall comments on the XSTEM study results * In discussions with investigator-initiated studies * We keep our fair value of SEl 1.04 per share Xintela’s year-end report did not reveal any substantial surprises. The recent rights issue and loan...

Xintela
Press release3/3/2026, 8:15 AM

Västra Hamnen Market Focus: Xintela: Moving forward with XSTEM

Xintela
Regulatory press release2/27/2026, 6:00 AM

Xintela AB Year-end Report 2025

Xintela
Press release2/17/2026, 10:07 AM

Västra Hamnen Market Focus: Professor Hall comments on Xintela's study results

Xintela
Press release2/13/2026, 1:50 PM

Xintela completes clinical study with XSTEM in difficult-to-heal leg ulcers

Xintela
Third party research12/12/2025, 10:17 AM

Xintela: Extending the financial runway - VH Corp

* The rights issue added MSEK 42 before loan offset * Fenja Capital II provides loan facility of MSEK 20 * After dilution, our fair value amounts to SEK 1.04 (1.28) per share Xintela’s recent rights issue was subscribed to 58 per cent, corresponding ...

Xintela
Press release12/12/2025, 9:49 AM

Västra Hamnen Market Focus: Xintela: Extending the financial runway

Xintela
Third party research11/12/2025, 9:20 AM

Xintela: Focus on study results and financing - VH Corp

• Final study results support XSTEM’s disease-modifying potential in OA • Rights issue of MSEK 72.8 announced at SEK 0.26 per share • Q&A with CEO Evy Lundgren Åkerlund on the new Targinta collaboration Xintela released its Q3 report on November 4 instead...

Xintela
Press release11/12/2025, 9:15 AM

Västra Hamnen Market Focus: Xintela: Focus on study results and financing

Xintela
Regulatory press release11/4/2025, 5:05 PM

Xintela AB Interim Report January - September 2025

Xintela
Press release10/30/2025, 7:15 AM

Last patient dosed in Xintela's clinical study on difficult-to-heal leg ulcers

Xintela